Amy S Cohen

US Patent:

20110274667, Nov 10, 2011

Filed:

Oct 19, 2009

Appl. No.:

13/124632

Inventors:

Anthony Donofrio - Westmont IL, US
Delara Motlagh - Barrington IL, US
David L. Amrani - Glendale WI, US
Amy Cohen - Grayslake IL, US

Assignee:

Baxter Healthcare S.A. - Glattpark (Opfikon)
Baxter International Inc. - Deerfield

International Classification:

A61K 35/12
A61P 9/10
A61P 13/12
A61P 37/06
A61P 27/02
A61P 17/02
C12N 5/077
A61P 3/10

US Classification:

424 937, 435325

Abstract:

Provided herein are methods of efficiently obtaining large numbers of viable, freshly isolated cells from small amounts of adipose tissue, as well as methods of enriching or selecting for target cell populations found therein. In certain embodiments, the method of obtaining a population of cells from adipose tissue comprises incubating the adipose tissue in a solution comprising an enzyme at a concentration which is at least 200 U/ml solution and not more than about 319 U/ml solution. In some embodiments, the method is devoid of any steps which expand the population of cells obtained. In certain aspects, the method further comprises positive or negative selection steps for obtaining an enriched population of target cells from adipose tissue. Related methods of preparing a pharmaceutical composition comprising cells for administration to a patient and methods of treating a disease or medical condition in a patient are further provided herein.

US Patent:

20130302290, Nov 14, 2013

Filed:

Jul 16, 2013

Appl. No.:

13/943448

Inventors:

- Glattpark (Opifkon), CH
Catherine M. Hoff - Lake Bluff IL, US
Amy Cohen - Grayslake IL, US
Jeremy Duffield - Seattle WA, US

International Classification:

A61K 35/28
A61K 45/06

US Classification:

424 937

Abstract:

Provided herein are methods of treating a kidney injury in a patient, comprising administering to the patient hematopoietic stem cells (HSCs) in an amount effective to treat the kidney injury. In some embodiments, administration of the HSCs is delayed, such that the HSCs are not administered immediately after the kidney injury. In certain aspects, the HSCs are administered to the patient during the beginning of the repair phase of the kidney. Further embodiments and aspects of the invention, including related methods and compositions for use therein, are described herein.